Valerie Jansen
-
Study examines new breast cancer drug combination
A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy. Read MoreApr 20, 2017
-
VICC investigators land Komen breast cancer grants
Two Vanderbilt-Ingram Cancer Center (VICC) investigators — Jennifer Pietenpol, Ph.D., B.F. Byrd Jr. Professor of Oncology and director of VICC, and Valerie Jansen, M.D., Ph.D., medical oncology fellow — have received new cancer research grants awarded by Susan G. Komen, the world’s largest nonprofit funder of breast cancer research. Read MoreOct 1, 2015